Oakridge Investments LLC increased its holdings in Eli Lilly and Company (NYSE:LLY – free report) by 3.8% in the first quarter, according to its latest filing with the Securities and Exchange Commission. The firm purchased an additional 2,030 shares during the period, bringing its holdings to 55,603 shares of the company. Eli Lilly and Company represents 4.4% of Oakridge Investments LLC’s investment portfolio, making it its fifth-largest position. Oakridge Investments LLC’s holdings in Eli Lilly and Company were worth $43,257,000 as of the latest SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. WealthPlan Investment Management LLC increased its holdings in Eli Lilly and Company by 13.5% in the third quarter. WealthPlan Investment Management LLC now owns 2,070 shares of the company’s stock, valued at $1,112,000, after purchasing an additional 247 shares during the period. Townsquare Capital LLC increased its holdings in Eli Lilly and Company by 189.0% in the third quarter. Townsquare Capital LLC now owns 19,377 shares of the company’s stock, valued at $10,408,000, after purchasing an additional 12,673 shares in the last quarter. Holderness Investments Co. increased its holdings in Eli Lilly and Company by 71.9% in the third quarter. Holderness Investments Inc. now owns 1,105 shares of the company’s stock, valued at $594,000, after purchasing an additional 462 shares in the last quarter. Integrated Wealth Concepts Inc. increased its holdings in Eli Lilly and Company by 2.5% in the third quarter. Integrated Wealth Concepts Inc. now owns 26,282 shares of the company’s stock, valued at $14,117,000, after purchasing an additional 641 shares in the last quarter. Finally, Pensera Capital Management Inc. increased its holdings in Eli Lilly and Company by 18.4% in the third quarter. Pensera Capital Management Inc. now owns 6,056 shares of the company’s stock, valued at $3,251,000, after purchasing an additional 940 shares in the last quarter. 82.53% of the stock is held by institutional investors.
Eli Lilly and Company shares up 1.8%
NYSE:LLY rose $16.47 to trade at $914.57 in midday trading on Friday. The company’s stock was traded at 2,880,863 shares, with an average trading volume of 2,607,195 shares. Eli Lilly and Company’s one-year low was $434.34 and its one-year high was $918.50. The company’s market capitalization is $869.22 billion, its price-to-earnings ratio is 134.69, its PEG ratio is 1.99 and its beta is 0.41. The company’s debt-to-equity ratio is 1.90, its current ratio is 1.35 and its quick ratio is 1.03. The company’s 50-day moving average price is $831.69 and its 200-day moving average price is $751.25.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Monday, May 6th. The company reported quarterly EPS of $2.58, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had net margins of 17.08% and return on equity of 56.98%. The company had revenues of $8.77 billion for the quarter, compared to analysts’ estimates of $8.94 billion. During the same period last year, the company earned $1.62 per share. The company’s revenue grew 26.0% year-over-year. Equity analysts expect Eli Lilly and Company to post EPS of $13.76 for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which is scheduled to be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30. The ex-dividend date is Thursday, August 15th. This equates to a $5.20 dividend on an annualized basis, or a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.
Insiders bet
In other Eli Lilly and Company news, the company’s largest shareholder, the Lilly Endowment, sold 8,848 shares of the company’s stock in a transaction that took place on Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the transaction, the insider now directly owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a document filed with the SEC, which can be accessed on the SEC’s website. In other Eli Lilly and Company news, the company’s largest shareholder, the Lilly Endowment, sold 8,848 shares of the company’s stock in a transaction that took place on Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the transaction, the insider now directly owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a document filed with the SEC, which can be accessed on the SEC’s website. Additionally, Executive Vice President, Johna Norton sold 7,056 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction value of $5,781,545.28. Following the completion of the transaction, the Executive Vice President now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold a total of 858,742 shares of the company’s stock in the last three months, valued at $735,573,781. 0.13% of the stock is currently owned by company insiders.
Wall Street analysts predict growth
Several research firms have recently issued their opinions on LLY. Morgan Stanley reaffirmed an “overweight” rating and set a $1,023.00 price target on shares of Eli Lilly and Company in a research report on Friday. Citigroup increased their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Truist Financial reaffirmed a “buy” rating and set a price target of $1,000.00 (previously $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. BMO Capital Markets reaffirmed an “outperform” rating and set a price target of $1,001.00 on shares of Eli Lilly and Company in a research report on Wednesday. Finally, Argus boosted their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Three investment analysts have rated the stock with a “hold” rating, and seventeen have given a “buy” rating. According to MarketBeat, Eli Lilly and Company has a consensus rating of “moderate buy” with an average price target of $816.78.
View the latest stock analysis for Eli Lilly and Company
Eli Lilly and Company Overview
(Free report)
Eli Lilly and Company discovers, develops and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamine, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for the treatment of diabetes; Jardiance, Mounjaro and Trulicity for the treatment of type 2 diabetes; and Zepbound for the treatment of obesity.
Feature Articles
Want to see if other hedge funds hold LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider transactions for Eli Lilly and Company (NYSE:LLY – Free Report).
Get daily Eli Lilly and Company news and reviews –Enter your email address below to receive a concise summary of the latest news and analyst ratings on Eli Lilly and Company and related companies every day with MarketBeat.com’s free email newsletter.
